REG-Oculis Announces Resignation of Lionel Carnot from Board of Directors
Key Highlights
- ➤Lionel Carnot resigns from Oculis’ (OCS) board, effective September 30, 2026
- ➤Board shrinks to eight members following Carnot’s departure
- ➤Geraldine O’Keeffe becomes chair of Oculis’ Remuneration Committee
- ➤Oculis will identify a successor; vacancy requires shareholder meeting approval
Expert Statements
Anthony Rosenberg, Chair of the Board of Oculis
“On behalf of the Board and the entire Oculis team, we wish to extend our sincere gratitude to Lionel for his invaluable service, leadership and guidance over nearly a decade, covering a transformative period for Oculis, where it evolved from a private startup company to a publicly listed late-stage biopharmaceutical company. His contributions to the Board and Oculis have been instrumental in our growth and evolution to become an emerging leader in neuro-ophthalmology.”
Lionel Carnot, Director of Oculis
“It has been a privilege to work alongside Oculis’ talented and dedicated team committed to addressing significant unmet medical needs and advance innovative solutions for patients suffering from ophthalmic and neuro-ophthalmic diseases. As the Company enters its next stage of growth, this is a timely point for me to step down and focus on other commitments. As an investor, I remain confident in the potential of Oculis’ pipeline and look forward to the Company achieving important milestones in the years ahead.”
ZUG, Switzerland, September 30, 2026 -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology, today announces that director Lionel Carnot will be resigning from the Board of Directors, effective today, after nearly a decade of dedicated service since 2017.
Anthony Rosenberg, Chair of the Board, remarked: “On behalf of the Board and the entire Oculis team, we wish to extend our sincere gratitude to Lionel for his invaluable service, leadership and guidance over nearly a decade, covering a transformative period for Oculis, where it evolved from a private startup company to a publicly listed late-stage biopharmaceutical company. His contributions to the Board and Oculis have been instrumental in our growth and evolution to become an emerging leader in neuro-ophthalmology.”
Get started
Create a free account to read the full story.